Regulation of RPE degeneration by REV-ERBalpha

REV-ERBalpha 对 RPE 变性的调节

基本信息

  • 批准号:
    10667553
  • 负责人:
  • 金额:
    $ 53.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-08-01 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

Project Summary Degeneration of retinal pigment epithelium (RPE) causes vision loss in age-related macular degeneration (AMD) and retinitis pigmentosa (RP). Promoting survival of RPE (and thereby photoreceptors) is critical for preserving vision. Whereas many factors contribute to RPE degeneration in eye diseases including both genetic and environmental ones, oxidative stress is one of the major contributors to RPE dysfunction and degeneration, derived primarily from excess mitochondrial oxidative products, and phagocytosis-related lipid oxidation. However, the processes through which dysregulated oxidative stress leads to RPE dysfunction and degeneration in eye diseases remain incompletely defined. Moreover, there is lack of effective approaches to promote RPE health and survival. Identification of the basic molecular links which sense RPE redox (reduction/oxidation) environment to impact RPE dysfunction and degeneration will aid in the identification of new molecular targets to rejuvenate endogenous cellular defense system in aging RPE and prevent vision loss in eye diseases. In this project we identified a redox-sensing nuclear receptor REV-ERBα, which may act as a transcriptional regulator linking RPE redox homeostasis and RPE antioxidant defense to impact RPE degeneration. REV-ERBα, functioning as a redox- and ligand-dependent transcription factor, controls multiple biological processes including cellular metabolism, inflammation, and circadian rhythm. Our preliminary results show that: 1) REV-ERBα levels decline with aging in RPE; 2) genetic deletion of REV-ERBα in mice leads to age-related development of RPE degeneration, with subretinal deposits, impaired visual function and dampened RPE phagocytic function; 3) RPE specific deletion of REV-ERBα causes similar fundus lesions; 4) REV-ERBα deficiency exacerbates chemically-induced induced RPE damage and retinal toxicity in vivo and in vitro; 4) activation of REV-ERBα protects RPE in vitro and in vivo; and 5) REV-ERBα directly regulates nuclear factor erythroid-2 related factor 2 (NRF2) transcription and its associated antioxidant genes. We hypothesize that REV-ERBα is a novel redox-sensitive regulator of RPE intracellular antioxidant defense system, and activating REV-ERBα is a new way to protect RPE. This hypothesis will be evaluated with both genetic and pharmacological approaches of modulating REV-ERBα in both acute and chronic models of RPE damage and degeneration. Mechanistically this work will explore whether REV-ERBα protects RPE vial enhancing RPE antioxidant self-defense. This proposed work will uncover novel molecular regulatory mechanisms underlying RPE degeneration, and new druggable molecular targets for developing improved strategies to counter RPE damage and degeneration in eye diseases.
项目摘要 老年性黄斑变性患者视网膜色素上皮(RPE)变性导致视力丧失 (AMD)和视网膜色素变性(RP)。促进RPE(从而光感受器)的存活对 保护视力。虽然许多因素导致眼部疾病的RPE变性,包括 在遗传和环境因素中,氧化应激是RPE功能障碍的主要因素之一。 变性,主要由过量的线粒体氧化产物和吞噬相关的脂质引起 氧化。然而,氧化应激失调导致RPE功能障碍和 眼科疾病中的变性仍然没有完全定义。此外,缺乏有效的方法来 促进RPE的健康和生存。识别识别RPE氧化还原反应的基本分子链 (还原/氧化)环境对RPE功能障碍和变性的影响将有助于识别 恢复老化RPE内源性细胞防御系统和预防视力丧失的新分子靶点 在眼科疾病方面。在这个项目中,我们确定了一个氧化还原敏感的核受体rev-erbα,它可能作为一种 连接RPE氧化还原动态平衡和RPE抗氧化防御的转录调控因子影响RPE 退化。REV-ERBα作为一种氧化还原和配体依赖的转录因子,控制着 生物过程,包括细胞新陈代谢、炎症和昼夜节律。我们的初步结果 结果表明:1)REV-ERBα水平随增龄而下降;2)小鼠REV-ERBα基因缺失导致 与年龄相关的RPE变性发展,伴有视网膜下沉积,视功能受损和 抑制RPE吞噬功能;3)RPE特异性缺失REV-ERBα导致类似的眼底损害;4) REV-ERBα缺乏加剧了化学诱导的视网膜色素上皮损伤和视网膜毒性 4)REV-ERBα在体内外对视网膜色素上皮细胞的保护作用;5)REV-ERBα直接调节细胞核 因子红系相关因子2(NRF2)转录及其相关的抗氧化基因。我们假设 REV-ERBα是RPE细胞内抗氧化防御系统的一种新的氧化还原敏感调节因子。 激活REV-ERBα是保护视网膜色素上皮的一种新方法。这一假说将用遗传学和 急性和慢性视网膜色素上皮损伤模型中调节REV-ERBα的药理学研究进展 退化。这项工作将从机制上探讨REV-ERBα是否保护小瓶增强的RPE 抗氧化剂自卫。这项拟议的工作将揭示新的分子调控机制 RPE变性和新的可药物分子靶点,用于开发抗RPE的改进策略 眼科疾病中的损害和退化。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Oxidative stress in retinal pigment epithelium degeneration: from pathogenesis to therapeutic targets in dry age-related macular degeneration.
  • DOI:
    10.4103/1673-5374.369098
  • 发表时间:
    2023-10
  • 期刊:
  • 影响因子:
    6.1
  • 作者:
    Maurya M;Bora K;Blomfield AK;Pavlovich MC;Huang S;Liu CH;Chen J
  • 通讯作者:
    Chen J
Oxidative Stress and Antioxidants in Age-Related Macular Degeneration.
Assessment of Inner Blood-Retinal Barrier: Animal Models and Methods.
  • DOI:
    10.3390/cells12202443
  • 发表时间:
    2023-10-12
  • 期刊:
  • 影响因子:
    6
  • 作者:
  • 通讯作者:
Endothelial Cell Transcytosis Assay as an In Vitro Model to Evaluate Inner Blood-Retinal Barrier Permeability.
  • DOI:
    10.3791/64076
  • 发表时间:
    2022-06-07
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Bora K;Wang Z;Yemanyi F;Maurya M;Blomfield AK;Tomita Y;Chen J
  • 通讯作者:
    Chen J
Amino acid transporter SLC38A5 regulates developmental and pathological retinal angiogenesis.
  • DOI:
    10.7554/elife.73105
  • 发表时间:
    2022-12-01
  • 期刊:
  • 影响因子:
    7.7
  • 作者:
    Wang Z;Yemanyi F;Blomfield AK;Bora K;Huang S;Liu CH;Britton WR;Cho SS;Tomita Y;Fu Z;Ma JX;Li WH;Chen J
  • 通讯作者:
    Chen J
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JING CHEN其他文献

JING CHEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JING CHEN', 18)}}的其他基金

Establishing A New Diagnostic Paradigm for Peripheral Artery Disease among Patients with Chronic Kidney Disease
建立慢性肾病患者周围动脉疾病的新诊断范式
  • 批准号:
    10465042
  • 财政年份:
    2021
  • 资助金额:
    $ 53.32万
  • 项目类别:
Establishing A New Diagnostic Paradigm for Peripheral Artery Disease among Patients with Chronic Kidney Disease
建立慢性肾病患者周围动脉疾病的新诊断范式
  • 批准号:
    10677577
  • 财政年份:
    2021
  • 资助金额:
    $ 53.32万
  • 项目类别:
Establishing A New Diagnostic Paradigm for Peripheral Artery Disease among Patients with Chronic Kidney Disease
建立慢性肾病患者周围动脉疾病的新诊断范式
  • 批准号:
    10186101
  • 财政年份:
    2021
  • 资助金额:
    $ 53.32万
  • 项目类别:
Regulation of RPE degeneration by REV-ERBalpha
REV-ERBalpha 对 RPE 变性的调节
  • 批准号:
    10218186
  • 财政年份:
    2020
  • 资助金额:
    $ 53.32万
  • 项目类别:
Regulation of RPE degeneration by REV-ERBalpha
REV-ERBalpha 对 RPE 变性的调节
  • 批准号:
    10448503
  • 财政年份:
    2020
  • 资助金额:
    $ 53.32万
  • 项目类别:
Regulation of RPE degeneration by REV-ERBalpha
REV-ERBalpha 对 RPE 变性的调节
  • 批准号:
    10029720
  • 财政年份:
    2020
  • 资助金额:
    $ 53.32万
  • 项目类别:
Wnt signaling-mediated control of blood-retinal barrier
Wnt信号介导的血视网膜屏障控制
  • 批准号:
    9918370
  • 财政年份:
    2017
  • 资助金额:
    $ 53.32万
  • 项目类别:
Clinical Research and Community Engagement Core
临床研究和社区参与核心
  • 批准号:
    10504810
  • 财政年份:
    2016
  • 资助金额:
    $ 53.32万
  • 项目类别:
Clinical Research and Community Engagement Core
临床研究和社区参与核心
  • 批准号:
    10664045
  • 财政年份:
    2016
  • 资助金额:
    $ 53.32万
  • 项目类别:
Urinary Angiotensinogen Excretion and Salt-Sensitivity of Blood Pressure
尿血管紧张素原排泄和血压的盐敏感性
  • 批准号:
    8697725
  • 财政年份:
    2014
  • 资助金额:
    $ 53.32万
  • 项目类别:

相似海外基金

Improving Acute Disease Management for Patients with Alzheimer's Disease and Related Dementias
改善阿尔茨海默病和相关痴呆症患者的急性疾病管理
  • 批准号:
    10712647
  • 财政年份:
    2001
  • 资助金额:
    $ 53.32万
  • 项目类别:
INDUCTION OF ACUTE DISEASE IN MACAQUES BY NEF GENE VARIANT OF SIVMAC239
SIVMAC239 的 NEF 基因变体在猕猴中诱导急性疾病
  • 批准号:
    6247642
  • 财政年份:
    1997
  • 资助金额:
    $ 53.32万
  • 项目类别:
INDUCTION OF ACUTE DISEASE IN MACAQUES BY NEF GENE VARIANT OF SIVMAC239
SIVMAC239 的 NEF 基因变体在猕猴中诱导急性疾病
  • 批准号:
    3718999
  • 财政年份:
  • 资助金额:
    $ 53.32万
  • 项目类别:
Neurophysiological alterations in multiple sclerosis patients during acute disease acivity
多发性硬化症患者急性疾病活动期间的神经生理学变化
  • 批准号:
    465668867
  • 财政年份:
  • 资助金额:
    $ 53.32万
  • 项目类别:
    Research Grants
SIVMAC 1NEF ALLELE: LYMPHOCYTE ACTIVATION & ACUTE DISEASE IN MACAQUE MONKEYS
SIVMAC 1NEF 等位基因:淋巴细胞激活
  • 批准号:
    3719026
  • 财政年份:
  • 资助金额:
    $ 53.32万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了